- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01840137
Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer
The development of clinically relevant and scalable exercise interventions in older cystectomy patients may have an impact upon:
- Patients: Exercise interventions may improve patient outcomes, including quality of life and avoidance of skilled nursing facilities.
- Clinicians: Proving the safety and feasibility of targeted interventions in older surgical patients may facilitate the development of clinically relevant preoperative interventions suitable for wider study and implementation.
- Payers: Improved surgical outcomes among high risk surgical patients will be associated with significant cost savings.
- Researchers: Targeted and well controlled studies focusing on improving surgical outcomes through exercise may provide insight into relationships between patient factors, surgical stressors and outcomes. Ultimately, such work may lead to novel clinical approaches to optimize patients for surgery.
The investigators will study the effects of preoperative exercise training on cystectomy patients, specifically targeting increasing functional capacity and muscular strength. Prior to conducting a more extensive, multi-center, randomized-controlled trial, the feasibility, safety, and initial efficacy of preoperative exercise in cystectomy patients must be determined. To address this issue, the investigators will complete a trial of rehabilitation in cystectomy patients at the University of Michigan.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have biopsy-proven bladder cancer.
- Patients age ≥60, diagnosed with bladder cancer with planned cystectomy and urinary diversion, +/- neoadjuvant chemotherapy.
- The patient must be able to communicate and understand/complete forms/instructions, and be able to provide informed written consent prior to enrollment. Patients may have the assistance of an interpreter or surrogate when completing forms/surveys as needed.
- Karnofsky performance status ≥70 with the ability to walk unassisted.
- Sedentary baseline lifestyle, with an average of <180 minutes/week of moderate-intensity aerobic activity.
- Attending surgeon clearance to undergo a supervised exercise training program.
Exclusion Criteria:
- Contraindication to exercise training, such as skeletal metastases, symptomatic coronary artery disease, severe anemia, or any condition limiting their ability to participate in an exercise training program.
- Patients who require surgery sooner than 28 days from enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Prehabilitation
The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks.
The first week of training will include an acclimation period accomplished via a ramping protocol.
Subjects will warm-up on a treadmill for 5-minutes.
Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression.
After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
|
A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
Treadmill and muscle exercises.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess whether a pre-operative exercise training program (Prehabilitation) for elderly patients undergoing cystectomy for bladder cancer will lower their post-operative 90-day hospital readmission rate.
Time Frame: 3 Years
|
The study will compare the readmission rate of 70 recruited prehabilitation patients to the historic readmission rates from our institution and the published literature.
Readmission will be defined as an admission to any acute care hospital after initial discharge from the immediate post-operative stay within 90 days of surgery.
Visits to emergency rooms or urgent, unscheduled outpatient evaluations will be tracked, but will not count as a readmission.
We will also track instances in which patients experience multiple re-admissions within 90 days of surgery, but for the purposes of this study, multiple re-admissions for an individual patient will only count as a single readmission event.
|
3 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine the efficacy of prehabilitation on improving functional capacity and strength from baseline levels.
Time Frame: 3 Years
|
A submaximal exercise test and 6 minute walk test will be used to assess the maximal rate of oxygen utilization and functional capacity at baseline and at the conclusion of the intervention period.
Muscular strength will be evaluated using volume loading.
|
3 Years
|
|
Composite of measures assessing the effects of prehabilitation on peri-operative cystectomy complications, resource utilization, patient reported outcomes, and functional status.
Time Frame: 3 years
|
Early (within 30 days of surgery) and late (between 31 and 90 days of surgery) complications, length of hospital stay, resource utilization (emergency room visits, need for sub-acute rehabilitation or nursing home stays, and the costs associated with this additional care) and post-operative outcomes, such as functional capacity and quality of life, will be evaluated and compared to historic data available in the published literature.
|
3 years
|
|
Evaluate safety for a prehabilitation program in elderly cystectomy patients.
Time Frame: 3 Years
|
The endpoint for safety is the prevalence of adverse events during study-related assessments and exercise training sessions.
|
3 Years
|
|
Rates of attrition for a prehabilitation program in elderly cystectomy patients.
Time Frame: 3 Years
|
Study attrition will be the rate at which patients drop out of the study.
|
3 Years
|
|
Rates of adherence for a prehabilitation program in elderly cystectomy patients.
Time Frame: 3 Years
|
Study adherence will be the percentage of prescribed exercise sessions each participant completes during the treatment period.
|
3 Years
|
|
Rates of accrual for a prehabilitation program in elderly cystectomy patients.
Time Frame: 3 Years
|
Track the study recruitment rate and, once patients have been screened by the study team and approached to participate, note the reasons that patients who choose not to participate give for their refusal (personal preference, medical comorbidities/deconditioning, perceived program intensity, time commitment for the study protocol, travel distance or lack of consistent means of travel).
|
3 Years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeffrey S. Montgomery, MD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00051581
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Medical Enterprises Ltd.TerminatedUrinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder CancerUnited States
Clinical Trials on Baseline Strength Test
-
Coloplast A/SCompleted
-
University of California, Los AngelesNational Watermelon Promotion BoardNot yet recruitingCardiometabolic Health Indicators | Whole-body Antioxidant CapacityUnited States
-
University of Illinois at Urbana-ChampaignUniversity of California, San Francisco; Mbarara University of Science and... and other collaboratorsTerminated
-
Ran ShiRecruitingStroke | Hemiplegia | Physical Disability | Rehabilitation; Tobacco UseChina
-
São Paulo State UniversityCompleted
-
Biruni UniversityAtlas UniversityCompletedChronic Obstructive Pulmonary DiseaseTurkey
-
Gazi UniversityActive, not recruitingPulmonary HypertensionTurkey
-
Gazi UniversityCompleted
-
Cairo UniversityNot yet recruitingSmartphone Addiction | De Quervain Tenosynovitis
-
Michael TomassonRecruiting